Mind the Gap: Risk of Bias in Pediatric Trials

Developing an Integrated Strategy to Support Pediatric and Perinatal Clinical Trials Across Canada

May 28, 2011

Michele Hamm, MSc

Alberta Research Centre for Health Evidence



Introduction

- Randomized controlled trials (RCTs) are the gold standard for decision-making regarding therapy, but they are not immune from bias.
- There is a growing body of literature documenting the limitations and methodological flaws of pediatric research.
- The introduction of bias into a trial can lead to the overestimation of treatment benefits or underestimation of treatment harms.

Objectives

1) To give an overview of the Cochrane Collaboration's Risk of Bias tool.

2) To describe a research program focused on the development and evaluation of a knowledge translation (**KT**) strategy that will increase awareness and promote methodological rigor among pediatric trialists.



Risk of Bias

- Cochrane Risk of Bias tool: based on empirical evidence demonstrating associations between various methodological characteristics and magnitude of effect estimates
- Six domains:
 - Sequence generation
 - Allocation concealment
 - Blinding
 - Incomplete outcome data
 - Selective outcome reporting
 - "Other" sources of bias



Descriptive Analysis of Pediatric Trials

- Objectives: To provide an overview of a representative sample of pediatric RCTs published in 2007 and assess the validity of their results.
- 300 randomly selected RCTs indexed in the Cochrane Central Register of Controlled Trials
- Data extraction:
 - publication and trial characteristics
 - outcomes and conclusions
 - methodological quality and reporting
 - trial registration and protocol characteristics

Hamm et al. BMC Pediatrics 2010; 10:96.



Risk of Bias Assessments by Domain (N=300)

Domain	Risk of bias assessments – n (%)		
	High	Unclear	Low
Sequence generation	8 (2.7%)	143 (47.7%)	149 (49.7%)
Allocation concealment	8 (2.7%)	217 (72.3%)	75 (25.0%)
Blinding	41 (13.7%)	108 (36.0%)	151 (50.3%)
Incomplete data	60 (20.0%)	53 (17.7%)	187 (62.3%)
Selective reporting	48 (16.0%)	6 (2.0%)	246 (82.0%)
Other sources of bias	85 (28.3%)	109 (36.3%)	106 (35.3%)
Overall risk of bias	178 (59.3%)	99 (33.0%)	23 (7.7%)



Effect Sizes and Risk of Bias

	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	IV, Random, 95% CI	IV, Random, 95% CI
1. High	0.28 [0.21, 0.35]	-+
2. Unclear	0.22 [0.15, 0.29]	— — • —
3. Low	0.16 [0.07, 0.25]	— —
		-0.2 -0.1 0 0.1 0.2



Quality of Pediatric Trials

- Thomson et al: trends in RCTs from 1948-2006 (*PLoS* One 2010;5:9)
- Hartling et al: 163 trials presented as abstracts from 1992-1995 (BMJ 2009; 339:b4012)
- Crocetti et al: 146 trials published in high impact journals in 2007-2008 (*Pediatrics 2010; 126(2):298-305*)
- Nor Aripin et al: 604 pharmacological trials from 2007 (*Paediatr Drugs 2010; 12(2):99-103*)



Survey of Pediatric Trialists

• *Objective:* To determine the barriers and facilitators faced by pediatric trialists in the design, conduct, and reporting of methodologically rigorous trials.



Survey Methods

- Internet-based survey (SurveyMonkey)
- Surveyed corresponding authors of pediatric trials published in 2008 and 2009
 - Entire sample of Canadian researchers (n=90)
 - Random sample of international researchers (n=600)
- Questions to determine:
 - 1) knowledge and awareness of bias
 - 2) perceived barriers and facilitators in conducting trials
 - 3) utility of potential KT strategies for future interventions



Survey Challenges

- 19.9% response rate (128/644; 46 undeliverable)
- SurveyMonkey to REDCap
- Sampled from MICYRN membership (n=163)
- 23.0% response rate (186/807)



1) Knowledge and awareness of bias

- Identification of bias: responses ranged from Strongly Agree to Strongly Disagree
- Self-rated confidence in understanding of bias: mean 5.4/7



- 2) Barriers and facilitators
 - Barriers:
 - Lack of sufficient funding (70.3%);
 - Overwhelming volume of literature (63.1%);
 - Logistics make it difficult to minimize bias (52.9%)
 - Open-ended responses: blinding, buy-in from clinicians and organizational leadership



2) Barriers and facilitators

- Facilitators:
 - Interest in staying current with literature (93.0%);
 - Opportunities to discuss methods with knowledgeable colleagues (92.8%);
 - Rigorous methods encouraged by colleagues (80.4%)
 - Open-ended responses: culture supportive of research, strong collaborators



3) KT strategies

- Checklists or reminders (90.7%)
- Online resource centre (88.7%)
- Lectures or seminars (76.7%)
- Opinion leaders (73.2%)
- Educational materials (62.0%)



Follow-up Interviews

• *Objective:* To gain greater insight into how researchers' beliefs and values related to working with children and their caregivers intersect with issues of study design.



Interview Methods

- MICYRN survey respondents invited to participate in an interview
- Semi-structured interviews building upon quantitative survey data
- Target sample size of 12 pediatric trialists
- Questions to determine:
 - Relationships between participants' beliefs, behaviours, and attitudes about conducting research on children and appropriate design and conduct of methodologically sound trials



Interview Results

Ongoing – 4 interviews conducted so far

Barriers:

- Blinding: type of interventions
- Logistics: fragmented ethics review system
- Conflict between clinical care and clinical research

Facilitators:

- Research networks
- Positive working relationships colleagues and sponsors
- Generating support prior to trial initiation



Future Directions

- Objectives: To design and evaluate a tailored KT intervention to improve methodological rigor in child health trials.
- Researcher involvement sought throughout
- Potential interventions: online module, checklists



Future Directions

- StaR Child Health
 - Risk of Bias Standard Development Group
 - Research agenda includes support for knowledge translation initiatives
 - Envision online support and resources for researchers



Discussion

- How do we engage trialists?
 - Reasons for low response rates?
- What is the optimal format for a KT intervention?
- Who is the optimal audience for a KT strategy?
 - Trainees?
 - Established researchers?



Acknowledgements

Dr. Lisa HartlingDr. Terry KlassenDr. Shannon ScottDr. David Moher



